PIN30: HOSPITALIZATION EXPENDITURE OF STREPTOCOCCUS PYOGENES-ASSOCIATED CELLULITIS IN THE UNITED STATES  by Liu, Z et al.
262 Abstracts
nomic evaluation of drug therapy. OBJECTIVES: This
was to assess the cost effectiveness of some antimicrobial
agents used in the treatment of sexually transmitted dis-
eases (STD). These include doxycycline versus tetracy-
cline for chlamydial infection, benzathine penicillin versus
procaine penicillin for syphilis, and ceftriaxone versus
spectinomycin for gonorrhoea. The choices were based on
standard treatment guidelines and observed prescrip-
tions. METHODS: Cost Effectiveness Analysis was used. 
The prescribed/dispensed prescriptions in STD clinic
between 1997 and 1999 were reviewed retrospectively.
Relevant information such as diagnosis, prescribed/
dispensed drugs, dosage, duration of therapy, laboratory
results, physician’s remarks among others were obtained
from patient case-notes and dispensed prescriptions. In
conjunction with these, time and motion studies and stan-
dard cost accounting technique were used. The cost per
deﬁned daily dose (DDD) and the cost of therapy for each
agent were calculated. The cost components include over-
head costs, and cost of drug/disposables acquisition. The
literature was reviewed for positive and negative conse-
quences of the considered therapeutic options. Improve-
ments in signs and symptoms as well as eradication of the
implicated organisms are the outcome measures. Decision
table was used in the effectiveness rating. These were
compared using chi square analysis. RESULTS: The
results showed that doxycycline, benzathine penicillin
and ceftriaxone were more effective than their respective
counterparts in the treatment of stated infections. For
example, doxycycline was N0.92 per unit effective while
tetracycline was N1.82 per unit effective. Tetracycline is
still widely used in the country. Alteration of some vari-
ables (cost and effectiveness rating) in favour of less cost
effective option did not change the conclusion conﬁrming
that doxycycline is truly more cost effective. CONCLU-
SION: It is concluded that tetracycline should no longer
be used except when doxycycline is not available. This
equally applies to benzathine penicillin and ceftriaxone
compared to their counterparts. However patients pecu-
liarities and contraindications need to be considered at all
times.
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OBJECTIVE: To determine the impact of Streptococcus
pyogenes (group A streptococcus, GAS) associated cel-
lulitis on hospital expenditure in the United States.
METHODS: This study analyzed data from the Health-
care Cost and Utilization Project (2000) funded by the
Agency for Healthcare Research and Quality. Hospital-
izations due to cellulitis were identiﬁed using ICD-9 codes
681–682 as principal diagnoses. We assumed that
30–50% of cellulitis-related hospitalizations were caused
by GAS. RESULTS: In 2000, there were approximately
110,000–183,000 hospitalizations due to GAS-associated
cellulitis. Adults aged 18–64 years accounted for 56% of
the hospitalizations, followed by the elderly (65 years 
and older, 36%) and children (<18 years, 8%). The most
common comorbid conditions associated with cellulitis
were hypertension (28%), diabetes mellitus (13%) and
congestive heart failure (10%). The mean and median
length of hospital stay for cellulitis were about ﬁve and
four days, respectively. Total annual hospitalization
charges for GAS-associated cellulitis were estimated at
$1.2–2.0 billion in year 2002 US dollars. Average charge
per hospital stay was about $10,500. CONCLUSIONS:
GAS-associated cellulitis represents a signiﬁcant eco-
nomic burden in the US. Total annual hospitalization
charges estimated for GAS-associated cellulitis are signif-
icantly higher than the recent estimate by the Institute of
Medicine (Vaccines for the 21st Century, A Tool for Deci-
sionmaking, 2000) for all GAS-associated hospitaliza-
tions (<$100 million).
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OBJECTIVES: Peginterferon alfa-2a (40KD)/ribavirin
(PEG) has been shown to produce a higher rate of sus-
tained virological response (SVR) than non-pegylated
combination therapy (non-PEG) in CHC, but the cost-
effectiveness of this improved efﬁcacy has not been
assessed. METHODS: We used a Markov model of
disease progression in which the cohorts of hepatitis C
virus (HCV) patients received PEG or non-PEG for either
48 or 24 weeks depending on genotype and liver histol-
ogy and were followed for their expected lifetime. The
reference patient was a 45-year-old male with CHC
without cirrhosis. The SVRs to PEG and non-PEG were
46% and 36% for HCV genotype 1 and 76% and 61%
for non-1, respectively. Quality of life and costs for each
health state were based on literature and on Italian treat-
ment patterns. Costs in 2002 Euros and beneﬁts were 
discounted at 3%. RESULTS: In HCV genotype 1, PEG
increases life expectancy (LY) by 0.78 years and quality-
adjusted life expectancy (QALY) by 0.67 years compared
to non-PEG. The incremental cost per QALY gained is
12,026 Euros. In HCV non-1 genotype patients, PEG
increases LY by 1.17 and QALY by 1.01 years in com-
